Huakang Shares released its 2026 interim report, with net profit attributable to the parent company of 41.964 million yuan, down 68.61% from the same period last year. Total operating revenue was 2.481 billion yuan, up 32.98% year-on-year, marking a second consecutive year of growth. Net cash inflow from operating activities was 107 million yuan, up 28.92% year-on-year. The company's latest asset-liability ratio was 59.91%, gross margin was 12.15%, ROE was 1.32%, and diluted earnings per share was 0.14 yuan.
Zhejiang Huakang Pharmaceutical Co LtdNet profit attributable to parent fell 68.61% year-on-year in the 2026 interim report.